“Normal wound healing is like a good story: there is a beginning, a middle, and an end,” Prof. Greg Goodman (Monash University, Australia) began his lecture [1]. Normal wound healing starts with an inflammatory phase (see Figure), with activation of the clotting cascade as well as action of cytokines and the attraction of immune cells. Next is the proliferative phase, which lasts for about 6-7 weeks. The fibrin plug is replaced by granulation tissue, fibroblasts generate collagen 3, extracellular matrix and re-epithelialisation takes place as keratinocytes migrate across the wound surface. Angiogenesis also induces the production of immature leaky blood vessels to allow easy access of nutrients. During the final remodelling phase, the granulation tissue changes from type 3 collagen to type 1, the immature vessels regress, and the now stronger scar tissue contracts.
Figure: The 3 phases of normal wound healing. Modified from [1]
“We need to think of keloids as a faulty switch in the transition from the proliferation to the remodelling phase with a failure of apoptotic control of reticular dermal healing,” explained Prof. Goodman. Overexpressed growth factors and increased activity by fibroblasts can be observed in keloids; proinflammatory factors continue to be upregulated; and a gap between extracellular matrix stiffness and cellular stiffness increases the likelihood of keloid progression [2]. Lastly, keloids have a 20-fold increase of collagen levels, the fibroblasts proliferate faster and the balance is lost between pro- and anti-inflammatory mediators [1]. There may be a genetic basis for the inability to turn of the proliferative phase and enter the remodelling phase. “We have a few details of what is abnormal and how it happens, but virtually no knowledge of why it happens,” concluded Prof. Goodman.
- Goodman G. 24th World Congress of Dermatology, 10-15 June 2019, Milan, Italy.
- Huang C et al. Int Wound J. 2017;14: 764-771.
Posted on
Previous Article
« Letter from the Editor Next Article
Cutaneous adverse events due to EGFR inhibitors »
« Letter from the Editor Next Article
Cutaneous adverse events due to EGFR inhibitors »
Table of Contents: WCD 2019
Featured articles
Letter from the Editor
Insights into pathogenesis of AD define novel therapeutic targets
Treating Psoriasis in 2019
Choosing the right biologic in psoriasis
Registries – an important research tool in biologics
Atopic Dermatitis – What is New
Insights into pathogenesis of AD define novel therapeutic targets
Combinations are hot in AD treatment
Dermal Reactions to Systemic Drugs
Cutaneous adverse events due to EGFR inhibitors
Management strategies for drug-induced mucositis
Skin toxicity of immune checkpoint inhibitors
Lupus Erythematosus Today
New targets and biologics for cutaneous lupus erythematosus
Novel lupus classification will aid future research
Hidradenitis Suppurativa
Various guidelines with much overlap
Antibiotics in hidradenitis suppurativa
Biologicals beyond TNF blockade
Small Molecules – What to Expect
Novel treatment options for many dermatologic indications
Long awaited oral therapy for moderate-to-severe AD
Novel treatment options in alopecia areata and vitiligo
Optimising the Management of Keloids
Keloids: a faulty switch in wound healing?
What the future of keloid treatment could hold
Malignant Melanoma – Advances in Management
Will malignant melanoma become a curable disease?
Best of the Posters
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy